Health Canada

Impressive $3.3M investment in Basic Mental Health Research

Retrieved on: 
Tuesday, March 19, 2024
Depression, Health, Basics, Mental health, Obesity, Prevalence, Drug discovery, University of Calgary, Insulin, Risk, Knowledge, Insulin resistance, The Honourable, Power Corporation of Canada, Research, Anxiety, University, Laboratory, Health Canada, Woman, Addiction, University of Toronto, Nursing

Basic research is scientific research carried out primarily to expand knowledge and understanding rather than to directly address clinical or practical issues.

Key Points: 
  • Basic research is scientific research carried out primarily to expand knowledge and understanding rather than to directly address clinical or practical issues.
  • The Basics of Better Mental Health Program funds basic research that will provide insight into the causes and onset of mental health conditions, explore the neuropathological changes and information-processing deficits that may eventually lead to new directions for treatments and interventions, and explore the role of sex and gender in mental health.
  • "Brain research plays a critical role in increasing our understanding of the causes and onset of mental health conditions,” says the Honourable Ya’ara Saks, Minister of Mental Health and Addictions.
  • “I am thrilled to support the work being done through the Basics of Better Mental Health Program – this work will support better mental health for all Canadians.”
    “The inclusion of sex-specific biological considerations is instrumental in understanding the biological roots of mental health conditions,” says Dr. Viviane Poupon, President and CEO of Brain Canada.

Titan Announces Merger Agreement with Conavi

Retrieved on: 
Monday, March 18, 2024
TSX Venture Exchange, Agreement, Health Canada, IP, OCT, RAS, Chairperson, Toronto Stock Exchange, Consolidation, Combined, Reverse, Concurrency, Food, TMD, TSX, Transaction, IVUS, Security (finance)

TORONTO, Ontario, March 18, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that it has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction.

Key Points: 
  • TORONTO, Ontario, March 18, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that it has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction.
  • Under the terms of the Agreement, Titan will acquire all of the issued and outstanding shares of Conavi (the “Conavi Shares”) and in exchange Conavi shareholders will be issued common shares of Titan (the “Combined Entity Shares”).
  • Throughout 2023, it was made clear to Titan that a merger with another RAS company was not a viable option and Titan broadened its search for a merger partner beyond RAS.
  • The Titan Board is unanimous in its decision to execute the Amalgamation Agreement and to recommend this Transaction to its shareholders (the “Titan Shareholders”).

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in

Retrieved on: 
Monday, March 18, 2024
Neurology, Headache, NDS, Patient, Contraindication, Nonsteroidal anti-inflammatory drug, Chronic pain, Migraine, Health Canada, Chemical patent, PALO, OPML, Patent, Therapy, FDA

ELYXYB® (celecoxib oral solution) is in the same class of agents, is fast acting, and has the potential to have the lowest gastrointestinal (GI) side effects of all NSAIDs.3

Key Points: 
  • ELYXYB® (celecoxib oral solution) is in the same class of agents, is fast acting, and has the potential to have the lowest gastrointestinal (GI) side effects of all NSAIDs.3
    The anticipated timeline for approval in Canada is approximately 12 months depending on review cycles and information requests by Health Canada.
  • ELYXYB®’s product profile mapped with a high degree of certainty to these stated unmet needs.
  • For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com .
  • For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com .

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 13, 2024
Administration, Patient, Regulatory affairs, Research, G&A, EMA, Doctor of Philosophy, DM1, Completeness, Health Canada, Senior, Net operating loss, IND, MHRA, Research and development, Duchenne muscular dystrophy, Clinical trial, Data management, Therapy, Vertex Pharmaceuticals, FDA, DMD, Medication, Pharmaceutical industry

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company today reported financial results for the fourth quarter and full year ending December 31, 2023, and highlighted recent business updates.

Key Points: 
  • The Company today reported financial results for the fourth quarter and full year ending December 31, 2023, and highlighted recent business updates.
  • “We continue to make significant progress advancing our growing pipeline of intracellular therapeutics,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.
  • Collaboration Revenue: Collaboration revenue was $41.8 million for the fourth quarter of 2023 and $129.0 million for the full year of 2023.
  • The G&A expenses in the fourth quarter of 2023 were lower than the fourth quarter of 2022 primarily due to a decrease in legal and consulting fees.

Revive Therapeutics Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
DRDC, Neuroprotection, Tremor, Diazepam, Chronic pain, COVID, Soman, National security, Survival, NAC, Seizure, Partnership, Nervous system, VX, COVID-19, Nerve agent, Patient, Brain, Heart rate, Research, Diarrhea, Endocytosis, RVV, Death, Doctor of Philosophy, Health Canada, Trial of the century, Cough, Traumatic brain injury, CDC, Harvard University, Fever, Sarin, Bleeding, Safety, Chemical warfare, Saliva, Therapy, Disorder, Blurred vision, FDA, Economics, Nerve, Hospital, Pharmaceutical industry

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.

Key Points: 
  • TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.
  • Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.
  • In addition, Revive may evaluate the potential of its proposed long COVID diagnostic product as a companion to Bucillamine.
  • The Company, under its wholly-owned subsidiary Revive Diagnostics Inc., is advancing the product development of a potential blood biomarker diagnostic that characterizes long COVID.

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy

Retrieved on: 
Thursday, April 4, 2024
Health, FDA, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Cell death, Medication, Survival, Wolfram syndrome, ALS, Partnership, Metabolism, Patient, AMX0035, Research, American Academy, OLE, Tauopathy, Health Canada, Biology, AAN, Clinical trial, Endoplasmic reticulum, Palsy, Workforce, Amylyx Pharmaceuticals, Division, Publication, Food, Vance DeGeneres, Pharmaceutical industry

Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.

Key Points: 
  • Amylyx will continue to evaluate and share learnings from PHOENIX to help inform future ALS research.
  • At this time, Amylyx intends to continue to collect available data on survival at the encouragement of ALS specialists.
  • “Our pipeline is supported by compelling clinical and preclinical science demonstrating the potential of AMX0035 and AMX0114 in neurodegenerative diseases.
  • “We are so thankful and grateful to our Amylyx team for their contributions and steadfast dedication,” said Cohen and Klee.

Aterian Investment Partners to Recapitalize CPL, a Leading Pharmaceutical Contract Development and Manufacturing Organization

Retrieved on: 
Monday, April 1, 2024
Other Manufacturing, Finance, Banking, Professional Services, Manufacturing, Biotechnology, Health, Pharmaceutical, General Health, CDMO, Partnership, Patient, History, Health Canada, Goodmans, Investment, European, Multimedia, FDA, Kirkland & Ellis, Pharmaceutical industry

Aterian Investment Partners (“Aterian”), a private investment firm, is pleased to announce that one of its affiliates has entered into an agreement to recapitalize Contract Pharmaceuticals Limited Canada ("CPL" or the “Company”), a leading North American contract development and manufacturing organization (CDMO) of non-sterile liquid and semi-solid dosage forms.

Key Points: 
  • Aterian Investment Partners (“Aterian”), a private investment firm, is pleased to announce that one of its affiliates has entered into an agreement to recapitalize Contract Pharmaceuticals Limited Canada ("CPL" or the “Company”), a leading North American contract development and manufacturing organization (CDMO) of non-sterile liquid and semi-solid dosage forms.
  • View the full release here: https://www.businesswire.com/news/home/20240401893587/en/
    CPL, based in Mississauga, Ontario, Canada, is an industry leader with longstanding relationships with 15 of the top 20 global pharmaceutical companies.
  • Further, CPL has a tremendous heritage of premier expertise and capabilities to offer customers a one-stop shop for all their development, manufacturing, packaging, and testing needs.
  • We look forward to working alongside CPL’s stakeholders on the Company’s next stage of growth.”
    Kirkland & Ellis LLP, and Osler, Hoskin & Harcourt LLP advised Aterian.

Cosm Medical Achieves FDA Clearance for Gynethotics™ Pessaries, Pioneering the future of personalized pelvic care

Retrieved on: 
Thursday, March 14, 2024
Research, Medical Devices, Medical Supplies, FDA, Clinical Trials, Other Health, Biotechnology, Health, Science, Other Science, Pessary, Medicine, Partnership, Patient, Journal, Incontinence, University, Femtech, Health Canada, Trial of the century, Woman, Gynaecology, Prolapse, Birth control

Cosm Medical proudly announces FDA clearance for Gynethotics™ Pessaries, marking it as the first personalized pessary available to patients.

Key Points: 
  • Cosm Medical proudly announces FDA clearance for Gynethotics™ Pessaries, marking it as the first personalized pessary available to patients.
  • This milestone follows a recent Health Canada clearance and marks a significant advancement in pelvic care, emphasizing Cosm’s commitment to enhancing patient outcomes and revolutionizing treatment options for women worldwide.
  • Gynethotics™ are the first pessary to be FDA cleared in about 5 years with almost 10 million pessary configurations that clinicians can conveniently order online.
  • “Our vision is to become the world leader in precision gynecological devices for unique bodies and needs.” said Derek Sham, Founder & CEO of Cosm Medical.

Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Retrieved on: 
Thursday, March 14, 2024
Neurology, Medical Devices, Health, Health Technology, Medical Supplies, CE marking, Physician, Health Canada, Patient, SNM, Lead, MRI, R20, Incontinence

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval.
  • The implant utilizes the same small 5cc form factor as the previous generation (Axonics R15™) and is paired with the same tined lead and intuitive, easy to use patient remote control.
  • The R20 represents another significant breakthrough for rechargeable neuromodulation devices and underscores Axonics’ commitment to continuous innovation.
  • The R20 received approval from the U.S. FDA in January 2023 and from Health Canada in December 2022.

United States Anesthesia Drugs Research Report 2024-2030 with Company Analysis of Baxter International, Abbvie, Medtronic, Draegerwerk, Koninklijke Philips, and Abbott Laboratories - ResearchAndMarkets.com

Retrieved on: 
Monday, March 11, 2024
Other Consumer, Manufacturing, Other Science, Pharmaceutical, Medical Devices, Hospitals, Consumer, Science, Practice Management, Dental, Managed Care, Medical Supplies, Biotechnology, Surgery, Health, Health Technology, Chemicals, Plastics, Health Insurance, Etomidate, Prevalence, Barbiturate, Isoflurane, Conditional sentence, Patient, Ache, Desflurane, National Cancer Institute, Anesthesiology, Local anesthesia, Health Canada, Survivor, Nitrous oxide, Lidocaine, Society, Cancer, Safety, Plastic, Benzocaine, Anesthetic vaporizer, Dentistry

The "United States Anesthesia Drugs Market, Size, Forecast 2024-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Anesthesia Drugs Market, Size, Forecast 2024-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The demand for anesthesia medicines is rising because of the growing number of surgeries and the approval of recent anesthesia drugs.
  • The United States Anesthesia Drugs Market is assessed into Inhalation Anesthesia, Intravenous Anesthesia, and Local Anesthesia.
  • The General Anesthesia Drugs Market is hastily advancing, specifically in the use of Sevoflurane, Desflurane, Isoflurane, and other inhalation anesthesia drugs.